De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Eisai Beheer

Beheer criteriumcontroles 1/4

De CEO Eisai's is Haruo Naito, benoemd in Jun2003, heeft een ambtstermijn van 21.33 jaar. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde ¥ 3.57B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 2.3 jaar.

Belangrijke informatie

Haruo Naito

Algemeen directeur

JP¥211.0m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	21.3yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Haruo Naito's beloning veranderd ten opzichte van Eisai's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	JP¥33b
Mar 31 2024	JP¥211m	n/a	JP¥42b
Dec 31 2023	n/a	n/a	JP¥45b
Sep 30 2023	n/a	n/a	JP¥48b
Jun 30 2023	n/a	n/a	JP¥49b
Mar 31 2023	JP¥157m	n/a	JP¥55b
Dec 31 2022	n/a	n/a	JP¥27b
Sep 30 2022	n/a	n/a	JP¥32b
Jun 30 2022	n/a	n/a	JP¥33b
Mar 31 2022	JP¥127m	JP¥89m	JP¥48b
Dec 31 2021	n/a	n/a	JP¥57b
Sep 30 2021	n/a	n/a	JP¥63b
Jun 30 2021	n/a	n/a	JP¥60b
Mar 31 2021	JP¥125m	JP¥89m	JP¥42b
Dec 31 2020	n/a	n/a	JP¥94b
Sep 30 2020	n/a	n/a	JP¥121b
Jun 30 2020	n/a	n/a	JP¥125b
Mar 31 2020	JP¥157m	JP¥89m	JP¥122b
Dec 31 2019	n/a	n/a	JP¥97b
Sep 30 2019	n/a	n/a	JP¥58b
Jun 30 2019	n/a	n/a	JP¥73b
Mar 31 2019	JP¥152m	JP¥89m	JP¥63b

Compensatie versus markt: De totale vergoeding ($USD 1.47M ) Haruo } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de JP markt ($USD 1.49M ).

Compensatie versus inkomsten: De beloning van Haruo is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Haruo Naito (77 yo)

21.3yrs

Tenure

JP¥211,000,000

Compensatie

Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Haruo Naito	CEO, Representative Corporate Officer & Director	21.3yrs	JP¥211.00m	0.23% ¥ 3.6b
Gary Hendler	Senior VP & President of EMEA Region	no data	JP¥218.00m	geen gegevens
Lynn D. Kramer	VP & Chief Clinical Officer	no data	JP¥297.00m	geen gegevens
Yanhui Feng	Senior Vice President	4.8yrs	JP¥189.00m	geen gegevens
Mitsuru Shomon	VP & CFO	1.3yrs	geen gegevens	geen gegevens
Keisuke Naito	Representative Corporate Officer	less than a year	geen gegevens	geen gegevens
Makoto Hoketsu	VP & Chief Information Officer	less than a year	geen gegevens	geen gegevens
Masatomi Akana	Senior VP	1.8yrs	geen gegevens	geen gegevens
Shin Kato	VP, General Counsel & Chief Compliance Officer	less than a year	geen gegevens	geen gegevens
Sayoko Sasaki	Vice President of Corporate Communications & Sustainability	2.8yrs	geen gegevens	geen gegevens
Teruyuki Masaka	VP, Chief HR Officer & Corporate Officer of General Affairs Japan Subsidiaries	2.8yrs	geen gegevens	geen gegevens
Takashi Owa	Senior VP & Chief Scientific Officer - Japan Medical Safety	no data	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4523 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Haruo Naito	CEO, Representative Corporate Officer & Director	10.3yrs	JP¥211.00m	0.23% ¥ 3.6b
Yuko Yasuda	Outside Independent Director	1.3yrs	geen gegevens	0.000020% ¥ 309.0k
Fumihiko Ike	Independent Outside Chairman	3.3yrs	geen gegevens	0.00035% ¥ 5.4m
Toru Moriyama	Outside Independent Director	1.3yrs	geen gegevens	0.00016% ¥ 2.5m
Kenta Takahashi	Director	less than a year	geen gegevens	0.0039% ¥ 60.2m
Ryota Miura	Independent Outside Director	3.3yrs	geen gegevens	0.00032% ¥ 4.9m
Hiroyuki Kato	Director	2.3yrs	geen gegevens	0.0030% ¥ 46.2m
Yoshiteru Kato	Director	3.3yrs	geen gegevens	0.0038% ¥ 58.4m
Yumiko Miwa	Independent Outside Director	4.3yrs	geen gegevens	0.00043% ¥ 6.6m
Richard Thornley	Outside Independent Director	2.3yrs	geen gegevens	geen gegevens
Takuji Kanai	Independent Outside Director	less than a year	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4523 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Eisai Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new directors

High number of new directors

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Recent updates

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

High number of new directors

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Now 21% overvalued

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of JP¥80.00 per share at 1.9% yield

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

New minor risk - Share price stability

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Consensus EPS estimates fall by 25%

Now 21% undervalued

Upcoming dividend of JP¥80.00 per share at 2.2% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Analyse CEO-vergoeding

CEO